Loblaw stock: Pharmacy data adds context ahead of results

Published on 10/31/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Loblaw stock enters the next reporting phase with new pharmacy-care metrics. Third-quarter results are scheduled for November 19.

Pharmacy metrics shape the outlook

Shoppers Drug Mart reported more than 1.7 million minor-ailment consultations and treatments in 2025.
Loblaw is scheduled to release third-quarter results on November 19, followed by a conference call.
The pharmacy figures add operating context but do not replace Loblaw's next consolidated financial report.

Loblaw, CA5394811015, Illustration mit AI erstellt.

Shoppers Drug Mart released its inaugural Health Outcomes Report on October 26, giving investors fresh operating context for Loblaw Companies Limited's pharmacy business. Loblaw stock traded at 44.50 euros on Lang & Schwarz at 10:33 CEST on Saturday, October 31, 2026. The quote is a weekend market indication without a verified Xetra comparison.

Pharmacy activity adds operating detail

According to GlobeNewswire, Shoppers Drug Mart pharmacists provided more than 1.7 million consultations and treatments for minor ailments in 2025. More than 85 percent of minor-ailment assessment appointments were booked for the same or next day.

The report also said that more than one-third of services delivered in Pharmacy Care Clinics in 2026 took place outside regular weekday hours. Additional reported outcomes included improving or resolved symptoms for 95 percent of Ontario patients receiving a minor-ailment assessment for a urinary tract infection, based on pharmacist follow-up calls.

These figures measure pharmacy activity and reported patient outcomes rather than Loblaw's consolidated revenue or profit. For investors, they provide a more specific view of the reach and access proposition within Shoppers Drug Mart while leaving financial execution to the next earnings release.

November results are next

Loblaw announced on October 22 that it will release its 2026 third-quarter results on November 19 at approximately 6:30 a.m. Eastern Time. The company said a conference call will follow at 10:00 a.m. Eastern Time. The schedule was published by Loblaw.

The release will give shareholders the next consolidated checkpoint on sales, margins and earnings. It will also show whether the operating context from the pharmacy report is accompanied by continued financial execution.

Investors can follow the real-time quote of Loblaw stock for the latest trading indication.

Canadian equities form part of the broader market setting; investors can follow the S&P/TSX Composite for the wider Canadian market.

Current market reports provide broader market context.

More news and analyses on Loblaw stock cover further company developments.